Vor Biopharma
Vor Biopharma’s recognition in this profile concerns its historical engineered hematopoietic stem-cell and targeted-therapy platform within Cell & Gene Therapy Developers. The subsequent operating changes described below should be distinguished from that historical assessed scope.
- Highest 2026 tier: Tier III
- Cell & Gene Therapy Developers
- 1 ranking category
Overview
Vor Biopharma’s recognition in this profile concerns its historical engineered hematopoietic stem-cell and targeted-therapy platform within Cell & Gene Therapy Developers. The subsequent operating changes described below should be distinguished from that historical assessed scope.
Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Vor Biopharma contributes a credible combination of these characteristics.
Published assessment: Top 30 Cell & Gene Therapy Developers 2026 — Vor Biopharma.
Firm facts
| Public identity | Vor Biopharma |
| Institution type | Cell & Gene Therapy Developers institution |
| Primary focus | Cell & Gene Therapy Developers |
| Highest 2026 ranking tier | Tier III |
Contents
Activities in published assessments
Top 30 Cell & Gene Therapy Developers 2026 — Vor Biopharma
Vor Biopharma’s recognition in this profile concerns its historical engineered hematopoietic stem-cell and targeted-therapy platform within Cell & Gene Therapy Developers. The subsequent operating changes described below should be distinguished from that historical assessed scope.
Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Vor Biopharma contributes a credible combination of these characteristics.
Principal activities
Vor Biopharma is assessed using public institutional information and category-specific editorial research.
Core capability
Cell & Gene Therapy Developers
Client relevance
Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.
Execution and verification
Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.
Sector and mandate coverage
Primary category
Cell & Gene Therapy Developers
Institutional context
Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.
Market position
Vor Biopharma is assessed using public institutional information and category-specific editorial research.
Vor Biopharma is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier III.
Competitive context
The relevant peer set varies by category, geography, client segment and mandate. Vor Biopharma should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.
Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.
Leadership and governance
Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.
Corporate and public information
The public-facing organization is identified here as Vor Biopharma. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.
Corporate and disclosure information
| Organization | Vor Biopharma |
| Verification note | Confirm legal entity, licenses, offices and engagement terms directly before appointment or use. |
Rankings and recognition
Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.
Related Economy analysis
Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:
- Healthcare Rankings and the New Economics of Expertise
- Healthcare Market Structure Is Opening a New Lane for Specialist Providers
- Healthcare Rankings and the New Geography of Distributed Care
Related institutions and subjects
Vor Biopharma Inc. was incorporated in Delaware on 30 December 2015. Its 2025 annual report identifies principal executive offices in Boston and describes a change in operating focus: the previous clinical and manufacturing programs were wound down in 2025, and the company in-licensed telitacicept for autoimmune-disease development outside Greater China in June 2025. It also reports a September 2025 agreement to sell intellectual property related to trem-cel and VCAR33 to SyzygyMed. The earlier cell-and-gene-therapy ranking recognition remains historical and should not be read as confirmation that those programs continue within Vor.
Institutional information
Vor Biopharma’s 2026 proxy reports beneficial ownership as of 15 April of 19.99% for RA Capital and 10.47% for TCG Crossover, alongside other disclosed investors. The calculations include specified exercisable warrants and ownership blockers. RemeGen is identified as a licensor and shareholder; the disclosure does not establish it as an acquirer or majority owner. Source 1; Source 2.
Sources and data transparency
Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.
- Healthcare Ranking — Top 30 Cell & Gene Therapy Developers 2026 — 2026 inclusion and tier classification.
- The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
- The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
- The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.
Corrections and Updates
Factual corrections, updated institutional information, and supporting references may be submitted through The Economy Portal. All proposed changes are subject to editorial verification before publication.
Institutional information updated: 4 November 2026. Category assessments retain the scope and dates of their linked ranking editions.